
Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Ann Falsey, MD, is a professor of Medicine at the University Of Rochester School Of Medicine. The focus of her research has been clinical and translational research in the field of respiratory viral infections in adults.